The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products

被引:1
|
作者
Horan, Aisling [1 ]
Warreth, Shada [2 ,3 ]
Hervig, Tor [1 ,4 ]
Waters, Allison [1 ,5 ]
机构
[1] Natl Blood Ctr, Irish Blood Transfus Serv, Jamess St, Dublin D08 NH5R, Ireland
[2] Technol Univ Dublin, Sch Chem & Pharmaceut Sci, Dublin, Ireland
[3] Natl Inst Bioproc Res & Training NIBRT, Belfield, Dublin, Ireland
[4] Trinity Coll Dublin, Sch Med, Dublin, Ireland
[5] Univ Coll Dublin, UCD Sch Publ Hlth Physiotherapy & Social Sci, Dublin, Ireland
关键词
advanced therapeutic medicinal products; ATMP; blood establishment; cellular therapy; GMP; Good Manufacturing Practice; Introduction;
D O I
10.1016/j.jcyt.2024.02.012
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background aims: The relationship between blood establishments and advanced cellular therapies is evident in several European countries, with some involved in research and development and/or in manufacturing. The aim of the present study was to understand the advanced therapy medicinal product (ATMP) infrastructural, regulatory and logistic requirements needed for the Irish Blood Transfusion Service to support advanced therapeutics in Ireland. Methods: An online survey consisting of 13 questions was distributed in a targeted manner to the identi fied ATMP stakeholders in Ireland, namely those working in industry, health care, regulatory agencies or education. Subject matter experts in the field were approached and interviewed to gain further insight into the relationship between blood and tissue establishments (BTEs) and ATMPs, to explore the advantages these institutions have in development and to highlight potential challenges for implementation. Results: In total, 84.9% of survey respondents stated that BTEs have a role in the development of advanced therapeutics. Key BTE services identi fied as applicable to the ATMP sector from both surveys and interviews include the provision of starting materials for research and manufacturing, donor management, use of existing quality and traceability frameworks, product logistic strategies and Good Manufacturing Practice. Challenges for BTE expansion into the sector currently include high costs associated with ATMPs, lack of expertise in these therapies, limited therapeutic populations and no national ATMP strategic plan for Ireland. Conclusions: Blood establishments have services and expertise that can be extended into the advanced therapy sector. The existing knowledge and skill base of BTEs in Ireland should be leveraged to accelerate the development of ATMP strategies for industry and healthcare. (c) 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页码:524 / 530
页数:7
相关论文
共 50 条
  • [1] A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe
    Delgadillo, Joaquin
    Kerkela, Erja
    Waters, Allison
    van den Akker, Emile
    Lechanteur, Chantal
    Baudoux, Etienne
    Gardiner, Nicola
    De Vos, John
    Vives, Joaquim
    CYTOTHERAPY, 2023, 25 (12) : 1259 - 1264
  • [2] The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products
    Lowdell, Mark W.
    Thomas, Amy
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (01) : 9 - 15
  • [3] Advanced Therapy Medicinal Products and the Changing Role of Academia
    Priesner, Christoph
    Hildebrandt, Martin
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2022, 49 (03) : 158 - 162
  • [4] Advanced therapy medicinal products in China: Regulation and development
    Lu, Jiaqi
    Xu, Longchang
    Wei, Wei
    He, Wu
    MEDCOMM, 2023, 4 (03):
  • [5] Participation of patients in the development of advanced therapy medicinal products
    Bignami, F.
    Kent, A. J.
    di Paola, M. Lipucci
    Meade, N.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2011, 54 (07) : 839 - 842
  • [6] Advanced therapy medicinal products
    Lozano-Blazquez, Ana
    Makridaki, Despina
    Plesan, Claudia Roxana
    Kohl, Stephanie
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (01) : 63 - 65
  • [7] Advanced therapy medicinal products
    Seitz, R.
    Schneider, C. K.
    Hengel, H.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2011, 54 (07) : 789 - 790
  • [8] THE REGULATION OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE AND THE ROLE OF ACADEMIA
    Pearce, K. F.
    Hildebrandt, M. O.
    Scheding, S.
    Koehl, U.
    Mischak-Weissinger, E.
    Hauser, A.
    Edinger, M.
    Greinix, H.
    Worel, N.
    Apperley, J.
    Lowdell, M. W.
    Dickinson, A. M.
    CYTOTHERAPY, 2013, 15 (04) : S51 - S52
  • [9] The regulation of advanced therapy medicinal products in Europe and the role of academia
    Lowdell, M. W.
    Pearce, K. F.
    Apperley, J.
    Dickinson, A. M.
    Edinger, M.
    Greinix, H.
    Hauser, A.
    Koehl, U.
    Mischak-Weissinger, E.
    Scheding, S.
    Worel, N.
    Hildebrandt, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S510 - S510
  • [10] Regulation of advanced therapy medicinal products in Europe and the role of academia
    Pearce, Kim F.
    Hildebrandt, Martin
    Greinix, Hildegard
    Scheding, Stefan
    Koehl, Ulrike
    Worel, Nina
    Apperley, Jane
    Edinger, Matthius
    Hauser, Andrea
    Mischak-Weissinger, Eva
    Dickinson, Anne M.
    Lowdell, Mark W.
    CYTOTHERAPY, 2014, 16 (03) : 289 - 297